Abstract:Although there are international guidelines on management of antithrombotics (anti-platelet agents and anticoagulants) in patients undergoing colonoscopic polypectomy, both clinicians’ adherence to guidelines and patients’ compliance to clinicians’ instructions are largely unknown. We previously reported in a retrospective study that less than 15% of clinicians documented their peri-endoscopy instructions on anti-thrombotic use. We aim to investigate prospectively clinician’s adherence to international guideline and patients’ compliance to clinicians’ instructions on peri-endoscopic management of antithrombotics. The Colonoscopy Registry was established in November 2017. It collects prospective data from patients on antithrombotics use undergoing elective colonoscopies in a tertiary referral center in Hong Kong. Demographic data, types and indications of antithrombotics, peri-endoscopic management, colonoscopic findings, 7-day and 6-month follow-up for resumption of antithrombotics, post-polypectomy bleeding and serious cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or death from a vascular cause) were collected. Peri-endoscopic management of antithrombotics is defined as thoroughly adherent to the guidelines developed by Asian Pacific Association of Gastroenterology and Asian Pacific Society for Digestive Endoscopy when all conditions are fulfilled: correct decision of withholding/resuming drug, appropriate drug discontinuation, INR <2.0 before colonoscopic polypectomy and appropriate use of bridging therapy in patients on warfarin. Patient’s compliance to clinicians’ instructions is defined whether the use of antithrombotics during the peri-endoscopy period is consistent with clinicians’ advice. Doctors’ adherence was captured from casenotes while patient’s compliance to clinicians’ instructions were collected at face-to-face interview. From November 2017 to September 2019, 610 patients receiving antithrombotics with colonoscopic polypectomy were recruited. One hundred percent, 41.2%, 71.4% of clinicians adhered to the guidelines for aspirin alone, clopidogrel alone, and dual antiplatelet therapy (DAPT), respectively. As for warfarin and direct oral anti-coagulant (DOAC), 10.2% and 41.1% of clinicians respectively has full adherence. Regarding patients’ compliance, 75.3%, 41.2% ,85.7%, 38.8% and 36.8% were compliant in aspirin-alone, clopidogrel alone, DAPT, warfarin, and DOAC, respectively. Twenty patients (3.3%) developed immediate polypectomy bleeding,17 patients (2.8%) had delayed polypectomy bleeding, and 7 had serious cardiovascular events within 6-months of colonoscopy. Both clinicians’ adherence to guidelines and patient’s compliance to instructions on clopidogrel and anticoagulant use were sub-optimal. More emphasis should be put to it.

Retrospective Analysis on the Management of Anticoagulants and Antiplatelet Agents for Scheduled Endoscopy

CONTROVERSY ON THE MANAGEMENT OF ANTICOAGULANTS AND ANTIPLATELET AGENTS FOR SCHEDULED ENDOSCOPY

Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines.

Questionnaire-Based Survey on Gastrointestinal Bleeding and Management of Antithrombotic Agents During Endoscopy among Asian Countries.

The Management of Direct Oral Anticoagulants for Colorectal Endoscopic Submucosal Dissection: A Multicenter Observational Study

[IDEN Consensus on Management of Antithrombotic Agents in Patients Undergoing Gastrointestinal Endoscopy]

Effects of Guidelines for Gastroenterological Endoscopy in Patients Undergoing Antithrombotic Treatment on Postoperative Bleeding after Endoscopic Submucosal Dissection for Early Gastric Cancer: A Propensity Score-Matching Analysis

International Digestive Endoscopy Network Consensus on the Management of Antithrombotic Agents in Patients Undergoing Gastrointestinal Endoscopy

Prevention of Gastrointestinal Events in Patients on Antithrombotic Therapy in the Peri‐endoscopy Period: Review of New Evidence and Recommendations from Recent Guidelines

Rates and risk factors of bleeding after gastric endoscopic submucosal dissection with continuous warfarin or 1‐day withdrawal of direct oral anticoagulants

Managing anticoagulation and antiplatelet medications in GI endoscopy: a survey comparing the East and the West

Clinicians' Adherence And Patients' Compliance To Guidelines For The Management Of Antithrombotics In Patients Undergoing Colonoscopic Polypectomy

Guidelines for endoscopic management of non‐variceal upper gastrointestinal bleeding

A systematic critical appraisal of clinical practice guidelines of antithrombotic agents in gastrointestinal endoscopy using the AGREE II tool

Potential of Direct Oral Anticoagulant in Bleeding After Gastric Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis

Impact of INR monitoring, reversal agent use, heparin bridging, and anticoagulant interruption on rebleeding and thromboembolism in acute gastrointestinal bleeding

Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines

Timing of Direct Oral Anticoagulants Resumption Following Colorectal Endoscopic Submucosal Dissection: A Nationwide Study in Japan

Cutting-Edge Technologies for Gastrointestinal Therapeutic Endoscopy

CLINICIAN INSTRUCTIONS ON MANAGEMENT OF ANTITHROMBOTICS BEFORE COLONOSCOPY: A RETROSPECTIVE ANALYSIS OF 4,777 PATIENTS IN ONE YEAR COHORT

Optimal direct oral anticoagulant for upper gastrointestinal endoscopic submucosal dissection